drugset
drugset / Trial / NCT07305116

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

NCT07305116 ↗

Phase 1 Recruiting 15 enrolled The Children's Hospital of Zhejiang University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B cell mediated autoimmune disease.

Timeline

Start
2025-12-01
Primary completion
2028-12
Completion
2029-12

Drugs

EvaluationDrugModalityDoseRoute
Subject UCAR T-cell Cell therapy — Intravenous

Indications

IgA glomerulonephritis anti-neutrophil cytoplasmic antibody-associated vasculitis idiopathic multidrug-resistant nephrotic syndrome systemic lupus erythematosus systemic sclerosis